Welcome to the official website of the FOCUS project, a European collaborative research project supported by the European Commission.
FOCUS stands for F
g for S
econdary cardiovascular Prevention and aims at testing a Fixed-Dose-Combination (FDC) pill for cardiovascular prevention and treatment in populations with diverse socio-economic characteristics. The recommendations drafted by FOCUS for improved use of medication in patients with ischemic heart disease will contribute to a more rapid adoption of FDC medication for the treatment of chronic diseases in medical practice, and to making medication more available and affordable for large numbers of patients in developed and developing countries.
FOCUS (2010-2014) was a 4.7-million Euros European project of the Seventh Framework Programme (FP7), partly funded by the European Commission and coordinated by the National Centre for Cardiovascular Research (CNIC by its Spanish acronym). Consortium Members
brought together research institutes, clinicians, pharmaceutical company, SMEs and scientific organisations across Europe and Latin America that will study the FDC concept in a variety of social and economic settings to investigate the effect of an FDC pill on patients’ adherence and on the improved efficiency of secondary prevention.
Dr. Valentín Fuster
General Director of Centro Nacional de Investigaciones Cardiovasculares (CNIC)
Principal Investigator for FOCUS
A summary of the study results and recommendations about the use of the Polypill are available in FOCUS final report.